News rilevanti dalla letteratura

In rosso le review, in verde gli RCT.

•  New England Journal of Medicine, 14 luglio 2021 | “Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents”
• New England Journal of Medicine, 30 giugno 2021 | “Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine”
• Nature medicine, 17 maggio 2021 | “Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection“
• The Lancet, 14 maggio 2021 | “Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial”
• New England Journal of Medicine, 5 maggio 2021 | “Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant”
• The Lancet, 1 maggio 2021 | “Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”
• MMWR, 27 aprile 2021 | “Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years — United States, January–March 2021”
• New England Journal of Medicine, 22 aprile 2021 | “Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19”
• New England Journal of Medicine, 21 aprile 2021 | “Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19”
• New England Journal of Medicine, 15 aprile 2021 | “BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting”
• New England Journal of Medicine, 9 aprile 2021 | “Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination”
• Nature Reviews Immunology, 6 aprile 2021 | “Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19”
• New England Journal of Medicine, 16 marzo 2021 | “Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant”
• Nature, 15 marzo 2021 | “Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7″
• The Lancet, 8 marzo 2021 | “Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis”
• New England Journal of Medicine, 4 marzo 2021 | “Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19”
• JAMA, 26 febbraio 2021 | “Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19A Systematic Review and Meta-analysis”
• New England Journal of Medicine, 24 febbraio 2021 | “BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting”
• New England Journal of Medicine, 18 febbraio 2021 | “Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults”
• New England Journal of Medicine, 18 febbraio 2021 | “A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia”
• New England Journal of Medicine , 21 gennaio 2021 | “REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19”
• New England Journal of Medicine , 21 gennaio 2021 | “SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19”
• New England Journal of Medicine , 6 gennaio 2021 | “Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults”
• New England Journal of Medicine , 30 dicembre 2020 | “Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine”
• New England Journal of Medicine, 10 dicembre 2020 | “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine”
• Editoriale, 10 dicembre 2020 | ” SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention”
• New England Journal of Medicine , 02 dicembre 2020 | “Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results”
•  New England Journal of Medicine, 2 dicembre 2020 | Editoriale: “A Large, Simple Trial Leading to Complex Questions”
•  New England Journal of Medicine , 24 novembre 2020 | “A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia”
• New England Journal of Medicine, 29 ottobre 2020 | “Humoral Immune Response to SARS-CoV-2 in Iceland”
• New England Journal of Medicine, 21 ottobre 2020 | “Efficacy of Tocilizumab in Patients Hospitalized with Covid-19”
• New England Journal of Medicine, 8 ottobre 2020 | “Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19”
• New England Journal of Medicine, 8 ottobre 2020| “Remdesivir for the Treatment of Covid-19 — Final Report”
• The Lancet, 5 ottobre 2020 | “Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial”
• – MMWR, 16 settembre 2020 | “Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 — COVID-NET, 13 States, March 1–August 22, 2020
• JAMA, 2 settembre 2020 | “Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19The CoDEX Randomized Clinical Trial”
• JAMA, 2 settembre 2020 | “Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19A Meta-analysis”
• Jama, 2 settembre 2020 (editoriale) | “Corticosteroids in COVID-19 ARDSEvidence and Hope During the Pandemic”
• JAMA, 21 agosto 2020 | “Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19A Randomized Clinical Trial”
• JAMA, 21 agosto 2020 (editoriale) | “Efficacy of Remdesivir in COVID-19”
• New England Journal of Medicine, 6 agosto 2020 | “A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19”
• The Lancet, 20 luglio 2020 | “Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial”
• The Lancet, 20 luglio 2020 | “Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial”
• The Lancet, 20 luglio 2020 (editoriale) | “Encouraging results from phase 1/2 COVID-19 vaccine trials”
• New England Journal of Medicine, 17 luglio 2020 | “Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report”
• Nature, 10 luglio 2020 | “Extrapulmonary manifestations of COVID-19”
• Nature, 3 luglio 2020 | “Six months of coronavirus: the mysteries scientists are still racing to solve”
• Nature, 30 giugno 2020 | “Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo’”
• Nature, 24 giugno 2020 | “Five ways to ensure that models serve society: a manifesto”
• New England Journal of Medicine, 3 giugno 2020 | “A Randomized Trial of Hydroxychloroquine as post- exposure Prophylaxis for Covid-19”
• New England Journal of Medicine, Editoriale, 3 giugno 2020 | “Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence”
• New England Journal of Medicine, 27 maggio 2020 | “Remdesivir for 5 or 10 Days in Patients with Severe Covid-19”
• New England Journal of Medicine (editoriale), 27 maggio 2020 | “Remdesivir — An Important First Step”
• New England Journal of Medicine , 22 maggio 2020 | “Remdesivir for the Treatment of Covid-19 – Preliminary Report”
• BMJ, 14 maggio 2020 | “Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial”
• BMJ, 14 maggio 2020 | “Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data”
• The Lancet, 8 maggio 2020 | “Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial”
• The Lancet, 8 maggio 2020 | Editoriale ”Interferon beta-1b and COVID-19”
• New England Journal of Medicine, 7 maggio 2020 | Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
• New England Journal of Medicine, 7 maggio 2020 | Editoriale “The Urgency of Care during the Covid-19 Pandemic – Learning as We Go”
• New England Journal of Medicine, 30 aprile 2020 |“Clinical Characteristics of Coronavirus Disease 2019 in China”
• Nature, 29 aprile 2020 | ”Hopes rise for coronavirus drug remdesivir”
• The Lancet, 29 aprile 2020 | “Remdesivir in adults with severe COVID-19: a randomised, double- blind, placebo-controlled, multicentre trial”
• The Lancet 29 aprile 2020 [editoriale] | “ Remdesivir for COVID-19: challenges of underpowered studies “
• Nature Medicine, 29 aprile 2020| ”Antibody responses to SARS-CoV-2 in patients with COVID-19”
• Nature Reviews Immunology, 28 aprile 2020 | “The trinity of COVID-19: immunity, inflammation and intervention”
• New England Journal of Medicine (NEJM), 24 aprile | “Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility”
• New England Journal of Medicine (NEJM), 24 April | Editorial “Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19”
• Science, 17 aprile 2020| ”How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes”
• JAMA, 13 aprile | “Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19) A Review”
•  The Lancet, 6 aprile | “Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendation”
• Nature, 1 aprile 2020 | “Virological assessment of hospitalized patients with COVID-2019”
• Imperial College London COVID-19 Response Team, 30 marzo | 2020 “Estimating the number of infections and the impact of non-pharmaceutical interventions on COVID-19 in 11 European countries”
• New England Journal of Medicine, 18 March 2020 | “Uno studio randomizzato sull’efficacia del trattamento con Lopinavir-Ritonavir (I Articolo)”
• New England Journal of Medicine, 18 marzo 2020 | “Uno studio randomizzato sull’efficacia del trattamento con Lopinavir-Ritonavir (II Articolo)”
•  New England Journal of Medicine, 17 marzo 2020 |“Uno studio sulla stabilità del virus SARS-Cov-2 su superfici esterne”
• Annals of Internal Medicine, 17 marzo 2020 | Coronavirus Disease 2019 (COVID-19): Protecting Hospitals From the Invisible
• Jama Networks, 2 marzo 2020 | COVID-19 New Insights on a Rapidly Changing Epidemic
• New England Journal of Medicine, 31 gennaio 2020 | “A NOVEL CORONAVIRUS EMERGING IN CHINA — KEY QUESTIONS FOR IMPACT ASSESSMENT”
• The Lancet, 24 gennaio 2020 | “ CLINICAL FEATURES OF PATIENTS INFECTED WITH 2019 NOVEL CORONAVIRUS IN WUHAN, CHINA”
• China CDC Weekly, 22 gennaio 2020| “Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province, 2019−2020″
• World Health Organization, 5 gennaio 2020|Pneumonia of unknown cause – China